These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 21803735)
1. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation. Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735 [TBL] [Abstract][Full Text] [Related]
2. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104 [TBL] [Abstract][Full Text] [Related]
3. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Bagci-Onder T; Wakimoto H; Anderegg M; Cameron C; Shah K Cancer Res; 2011 Jan; 71(1):154-63. PubMed ID: 21084267 [TBL] [Abstract][Full Text] [Related]
4. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Mazzoletti M; Bortolin F; Brunelli L; Pastorelli R; Di Giandomenico S; Erba E; Ubezio P; Broggini M Cancer Res; 2011 Jul; 71(13):4573-84. PubMed ID: 21602434 [TBL] [Abstract][Full Text] [Related]
14. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890 [TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820 [TBL] [Abstract][Full Text] [Related]
16. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710 [TBL] [Abstract][Full Text] [Related]
17. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Marfe G; Di Stefano C; Gambacurta A; Ottone T; Martini V; Abruzzese E; Mologni L; Sinibaldi-Salimei P; de Fabritis P; Gambacorti-Passerini C; Amadori S; Birge RB Exp Hematol; 2011 Jun; 39(6):653-665.e6. PubMed ID: 21392556 [TBL] [Abstract][Full Text] [Related]
18. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725 [TBL] [Abstract][Full Text] [Related]
19. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587 [TBL] [Abstract][Full Text] [Related]
20. Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling. van de Laar L; Buitenhuis M; Wensveen FM; Janssen HL; Coffer PJ; Woltman AM J Immunol; 2010 Jun; 184(12):6600-11. PubMed ID: 20488790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]